CNS Pharmaceuticals, Inc.
CNSP
$5.52
-$0.60-9.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.74% | 1.56% | 14.00% | 23.58% | 17.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.28% | -22.72% | -2.57% | -10.23% | -21.01% |
| Operating Income | -7.28% | 22.72% | 2.57% | 10.23% | 21.01% |
| Income Before Tax | -6.68% | 23.37% | 3.22% | 10.59% | 21.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.68% | 23.37% | 3.22% | 10.59% | 21.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.68% | 23.37% | 3.22% | 10.59% | 21.18% |
| EBIT | -7.28% | 22.72% | 2.57% | 10.23% | 21.01% |
| EBITDA | -7.28% | 22.73% | 2.57% | 10.23% | 21.01% |
| EPS Basic | 78.37% | 56.53% | -- | -- | -- |
| Normalized Basic EPS | 78.37% | 56.53% | -- | -- | -- |
| EPS Diluted | 78.35% | 56.51% | -- | -- | -- |
| Normalized Diluted EPS | 78.37% | 56.53% | -- | -- | -- |
| Average Basic Shares Outstanding | 1,303.65% | 3,303.55% | -- | -- | -- |
| Average Diluted Shares Outstanding | 1,303.65% | 3,303.55% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |